78 related articles for article (PubMed ID: 17489744)
1. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
4. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Villa A; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Lombardi AV; Sorio R; Mangili G; Priolo D; Magni G; Morabito A
BMC Cancer; 2008 Sep; 8():252. PubMed ID: 18761742
[TBL] [Abstract][Full Text] [Related]
5. P-suPAR may reflect the inflammatory response after pancreatic surgery.
Aronen A; Aittoniemi J; Huttunen R; Siiki A; Antila A; Sand J; Laukkarinen J
Pancreatology; 2024 Feb; 24(1):146-151. PubMed ID: 38000982
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Memarzadeh S; Kozak KR; Chang L; Natarajan S; Shintaku P; Reddy ST; Farias-Eisner R
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10647-52. PubMed ID: 12130664
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort study.
Reisinger AC; Hatzl S; Prattes J; Hackl G; Schilcher G; Eisner F; Niedrist T; Raggam R; Krause R; Eller P
Infection; 2024 Feb; 52(1):249-252. PubMed ID: 37973717
[TBL] [Abstract][Full Text] [Related]
8. Periodontal Clinicoradiographic Status and Whole Saliva Soluble Urokinase Plasminogen Activation Receptor and Tumor Necrosis Factor Alpha Levels in Type-2 Diabetic and Non-diabetic Individuals.
Ali D; Qasem SS; Baskaradoss JK
Oral Health Prev Dent; 2021 Jan; 19():481-488. PubMed ID: 34585873
[TBL] [Abstract][Full Text] [Related]
9. The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer.
Blomberg K; Hansen TF; Brasen CL; Madsen JB; Jensen LH; Thomsen CB
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680247
[TBL] [Abstract][Full Text] [Related]
10. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Kenny HA; Leonhardt P; Ladanyi A; Yamada SD; Montag A; Im HK; Jagadeeswaran S; Shaw DE; Mazar AP; Lengyel E
Clin Cancer Res; 2011 Feb; 17(3):459-71. PubMed ID: 21149615
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.
Chu J; Tung L; Atallah I; Wei C; Cobleigh M; Rao R; Feinstein SB; Usha L; Banach K; Reiser J; Okwuosa TM
Cardiooncology; 2024 Jan; 10(1):3. PubMed ID: 38225669
[TBL] [Abstract][Full Text] [Related]
12. Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults.
Teo A; Le CTT; Tan T; Chia PY; Yeo TW
Clin Infect Dis; 2024 Mar; 78(3):788-796. PubMed ID: 37823481
[TBL] [Abstract][Full Text] [Related]
13. Gene Association Study of the Urokinase Plasminogen Activator and Its Receptor Gene in Alzheimer's Disease.
Cetinsoy O; Anyanwu I; Krishnanand H; Natarajan G; Ramachandran N; Thomas A; Brookes KJ
J Alzheimers Dis; 2024; 99(1):241-250. PubMed ID: 38669542
[TBL] [Abstract][Full Text] [Related]
14. Assay-related differences in SuPAR levels: implications for measurement and data interpretation.
Vasbinder A; Raffield LM; Gao Y; Engstrom G; Quyyumi AA; Reiner AP; Reiser J; Hayek SS
J Nephrol; 2023 Jan; 36(1):157-159. PubMed ID: 35567697
[No Abstract] [Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor, platelet aggregation, and carotid plaque thickness in diabetes: A cross-sectional analysis.
Rotbain Curovic V; Tavenier J; Ferreira-Divino LF; Poulsen CG; Houlind MB; Pedersen OB; Urbak L; Hansen TW; Sillesen H; Frimodt-Møller M; Hvas AM; Rossing P
J Diabetes Complications; 2024 Jan; 38(1):108654. PubMed ID: 38042098
[No Abstract] [Full Text] [Related]
16. Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
Shoji T; Tatsuki S; Abe M; Tomabechi H; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Baba T; Itamochi H
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885229
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma soluble urokinase plasminogen activator receptor levels across pregnancy and in relation to hypertensive disorders.
Cowell W; Limaye M; Brukbaker SG; Silverstein JS; Mehta-Lee SS; Kahn LG; Malaga-Dieguez L; Reiser J; Trasande L
Am J Obstet Gynecol MFM; 2023 May; 5(5):100825. PubMed ID: 36775198
[No Abstract] [Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor (suRAR) levels: underscoring the link between low educational attainment and death among coronary artery disease patients.
Coelho-Filho OR; Santos RD
Eur J Prev Cardiol; 2024 Mar; 31(5):519-520. PubMed ID: 37939795
[No Abstract] [Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia.
Zahr RS; Rashkin SR; Ruiz MA; Elsherif L; Ren G; Salas G; Ataga KI; Gordeuk VR; Lebensburger J; Zhang X; Saraf SL
Haematologica; 2024 May; ():. PubMed ID: 38695132
[TBL] [Abstract][Full Text] [Related]
20. Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: Observational single center study.
Beleva E; Stoencheva S; Deneva T; Nenova I; Grudeva-Popova Z
Biomol Biomed; 2023 Mar; 23(2):287-297. PubMed ID: 36124441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
